1[1]Levine B, Kalman J, Mayer L et al. Elevated circulating levels of tumor necrosis factor in congestive heart failure[J]. N Engl J Med, 1990;323:236
2[2]Bryant D, Becker L, Richardson J et al. Cardiac failure in transgenic mice with myocardial expression of tunnor necrosis factor-alpha[J] .Circulation,1998;97:1375
3[3]Kapadia S,Torre A G, Yokoyama T et al. Soluble TNF binding roteins modulate the negative inotropic properties of TNF-α in vitro [ J ]. Am J Physiol, 1995 ;268:H517
4[4]AbrahamE,CoulsonWF,SchwartzMDetal. Effect of therapy with soluble tumor necrosis factor receptor fusion protein on pulmonary cytokine expression and lung injury following hemorrage and resuscitstion[J]. Clin Exp Immuno, 1994;98:29
5[5]Diez R A,Tile G P, Zangerle R et al. Soluble reesptors for tumor necrosis factor in clinical laboratory diagnois[J].Eur J Haematd, 1995;54:1
6[6]J Koller-Strametz,Packer R, Frey B et al. Circulating tumor necrosis factor-alpha levels in chronic heart failure:relation to its soluble receptor Ⅱ,interleukin-6 and neurohornmonal variables[J]. J Heart Lung Transplant,1998;17:356
7[7]Parissis J, Venetsanon K,Mentzkof D et al. Clinical relevance of cytokine receptor soluble forms in decompensated advanced hesrt failure[J]. Eur Heart J, 1998; 19(suppl) :2661
8[8]Paulus W J.How are cytokine activated in heart failure[J]? F ur J Heart Fail, 1999; 1:309
9[9]Suzuki K,Murtuza B,FRCS M A et al. Overexpression of interleukine-2receptor antagonst provides cardlioprotection against ischemia reperfusion injury associated with reduction in apoptosis[J]. Circulation, 2001; 104:(12)1308
10[10]MarriotJB,GddmanJH,KeelingPJ et al. Abnonnal cytokine profiles in patients with idiopathic dilated cardomyopathy and their asymptomatic relatives[J]. Heart, 1996;75:287
3[6]Feldman AM,Combes A,Wagner D,et al.The role of tumor necrosis factor in the pathophysiology of heart failure[J].J Am Coll Cardiol,2000,35:537-544.
4[9]Kanda T,Takahashi T.Interleukin-6 and cardiovascular diseases[J].Jpn Heart J,2004,45:183-193.
5[10]Redevoe DL,Widawski M,Fonarow GC,et al.Interleukin-6(IL-6)expression and natural killer(NK)cell dysfunction and anergy in heart failure[J].Am J Cardiol,2004,93:1007-1011.
6[12]Pan JP,Liu TY,Chiang SC,et al.The value of plasma levels of tumor necrosis factor-alpha and interleukin-6 in predicting the severity and prognosis in patients with congestive heart failure[J].J Chin Med Assoc,2004,67:222-228.
7[13]Parissis JT,Adamopoulos S,Antaniades C,et al.Effects of levesimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure[J].Am J Cardiol,2004,93:1309-1312.
8[14]Shioi T,Matsumori A,Matoba Y,et al.Inhibition of cytokine production by a new inotropic agent veanarinone,in human lymphocytes.T cell line,and monocytic cell line[J].Life Sci,1994,54:PL11-16.
9[15]Ohtsuka T,Hamada M,Hiasa G,et al.Effects of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy[J].J Am Coll Cardiol,2001,37:412.
10[16]Matsumori A,Ono K,Nishio R,et al.Amiodarone inhibits production of tumor necrosis factor-a by human mononuclear cells[J].Circulation,1997,96:1386-1389.
